Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Rayson

Showing results (81-90 of 86) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 86 results.
JAMA Oncology|February 26, 2016
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-AnalysisKristine R Broglio, Melanie Quintana, Margaret Foster, et al.
Breast Cancer Research and Treatment|June 14, 2014
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY studyMark J Clemons, Brandy Cochrane, Gregory R Pond, et al.
Cancer Treatment Reviews|May 30, 2016
Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensusSimron Singh, Sylvia L Asa, Chris Dey, et al.
Breast Cancer Research and Treatment|April 27, 2016
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancerDaniel Rayson, Sasha Lupichuk, Kylea Potvin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancerEva Grunfeld, Jim A Julian, Gregory Pond, et al.
The Canadian Journal of Cardiology|June 26, 2016
Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer TherapySean A Virani, Susan Dent, Christine Brezden-Masley, et al.
Pageof 9

Showing results (81-90 of 86) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 86 results.
JAMA Oncology|February 26, 2016
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-AnalysisKristine R Broglio, Melanie Quintana, Margaret Foster, et al.
Breast Cancer Research and Treatment|June 14, 2014
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY studyMark J Clemons, Brandy Cochrane, Gregory R Pond, et al.
Cancer Treatment Reviews|May 30, 2016
Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensusSimron Singh, Sylvia L Asa, Chris Dey, et al.
Breast Cancer Research and Treatment|April 27, 2016
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancerDaniel Rayson, Sasha Lupichuk, Kylea Potvin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2011
Evaluating survivorship care plans: results of a randomized, clinical trial of patients with breast cancerEva Grunfeld, Jim A Julian, Gregory Pond, et al.
The Canadian Journal of Cardiology|June 26, 2016
Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer TherapySean A Virani, Susan Dent, Christine Brezden-Masley, et al.
Pageof 9